Orexo sues Actavis and Teva over narcotic dependency treatment
20-06-2017
ADragan / iStockphoto.com
The US Court of Appeals for the Federal Circuit yesterday revived a patent infringement lawsuit against Teva Pharmaceuticals, in a win for Sweden-based Orexo.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Teva, Orexo, Actavis, generic drugs, opiate treatment, Zubsolv, patent infringement, patent invalidation, obviousness, prior art, Suboxone
